21 CFR Part 880 · General Hospital and Personal Use Devices

21 CFR 880.5690

Infant supine sleep system

21 CFR 880.5690 is the regulation titled “Infant supine sleep system” in 21 CFR Part 880, General Hospital and Personal Use Devices. Since 2021, 1 FDA warning letter has cited it.

Letters citing it
1 since 2021
Jan 1 to Oct 30, 2026
1 against 0 on the same dates in 2025
Most often cited with
21 CFR 801.4, in 1 letter
Closed out
0% of these letters have a published close-out
See the letter citing 21 CFR 880.5690 →

Letters citing it, by year issued

It is a medical device letter. 2026 runs to Oct 30, 2026. Pick a year to see its letters.

  1. 02021
  2. 02022
  3. 02023
  4. 02024
  5. 02025
  6. 12026

The regulation

Read the text of 21 CFR 880.5690 (eCFR, as of Sep 1, 2026)

(a) Identification. An infant supine sleep system is a device intended to facilitate a supine position during sleep for use in infants that are not yet able to roll over consistently. Infants placed in a supine sleep position are at lower risk of sudden infant death syndrome (SIDS) or sudden unexpected infant death (SUID).

(b) Classification. Class II (special controls). The special controls for this device are:

(1) Premarket clinical information and, as determined by FDA, postmarket surveillance data acquired under anticipated conditions of use must be collected to fulfill the following:

(i) Demonstrate that the device holds the infant on the back;

(ii) Provide data on adverse events (including deaths and injuries) and malfunctions to demonstrate the device can be safely used in the intended use population; and

(iii) Provide data to demonstrate that use of the device does not increase the rate of SIDS/SUID in the intended use population.

(2) Human factors testing must demonstrate that the user can safely and correctly use the device.

(3) The patient-contacting components of the device must be demonstrated to be biocompatible.

(4) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. The following must be conducted:

(i) Testing to ensure the mechanical and structural stability of the device and demonstrate that the device does not present a tipping hazard due to mechanical failures; and

(ii) Material compatibility testing to demonstrate that the cleaning instructions provided by the manufacturer do not cause crazing, cracking, or deterioration of the device.

(5) Labeling must include:

(i) Unless clinical performance data demonstrates that it can be removed or modified, a prominent warning that the device has not been demonstrated to reduce the risk of SIDS/SUID. Such warning must appear prominently on all labeling;

(ii) A summary of available clinical information with the device, including a discussion of adverse events;

(iii) A warning that the device is only indicated for use with infants who cannot consistently roll over;

(iv) Instructions to ensure proper fit;

(v) Instructions for cleaning the device; and

(vi) Information regarding safe sleep practices to ensure the safe use of the device, including:

(A) Recommendations for safe sleep environments; and

(B) The level of supervision necessary to monitor a sleeping infant.

[91 FR 38508, June 26, 2026]

Text from eCFR as of Sep 1, 2026.

Cited alongside it

Regulations that appear in the same letters as 21 CFR 880.5690.

Latest letters citing it

The letter citing 21 CFR 880.5690 that FDA posted most recently.

See the letter citing 21 CFR 880.5690 →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Counts include every citation in a letter, as the Letters filter does. How this database is built.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.